Equities research analysts predict that Amicus Therapeutics (NASDAQ:FOLD) will post earnings of ($0.33) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Amicus Therapeutics’ earnings. Amicus Therapeutics reported earnings per share of ($0.34) in the same quarter last year, which would suggest a positive year-over-year growth rate of 2.9%. The business is expected to announce its next earnings results on Monday, August 6th.

On average, analysts expect that Amicus Therapeutics will report full year earnings of ($1.27) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($0.99). For the next financial year, analysts anticipate that the company will report earnings of ($0.98) per share, with EPS estimates ranging from ($1.42) to ($0.47). Zacks’ EPS calculations are an average based on a survey of analysts that follow Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.08. Amicus Therapeutics had a negative return on equity of 60.09% and a negative net margin of 563.98%. The firm had revenue of $16.70 million during the quarter, compared to the consensus estimate of $16.78 million.

Several equities analysts have weighed in on the company. Robert W. Baird set a $20.00 price target on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 7th. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, April 13th. ValuEngine raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Cowen reissued a “buy” rating and set a $22.00 price target on shares of Amicus Therapeutics in a research report on Tuesday, May 8th. Finally, Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 6th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Amicus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $19.06.

In other news, insider Hung Do sold 25,000 shares of the firm’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $15.00, for a total transaction of $375,000.00. Following the sale, the insider now owns 421,771 shares in the company, valued at $6,326,565. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William D. Baird III sold 10,000 shares of the firm’s stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $14.26, for a total value of $142,600.00. Following the sale, the chief financial officer now owns 127,662 shares in the company, valued at approximately $1,820,460.12. The disclosure for this sale can be found here. Insiders have sold 136,899 shares of company stock valued at $2,035,875 in the last three months. 2.90% of the stock is currently owned by company insiders.

Several hedge funds have recently bought and sold shares of FOLD. California Public Employees Retirement System boosted its holdings in shares of Amicus Therapeutics by 2.4% during the third quarter. California Public Employees Retirement System now owns 181,000 shares of the biopharmaceutical company’s stock worth $2,729,000 after purchasing an additional 4,200 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Amicus Therapeutics by 4.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 763,775 shares of the biopharmaceutical company’s stock worth $10,991,000 after purchasing an additional 31,900 shares during the last quarter. GW&K Investment Management LLC boosted its holdings in shares of Amicus Therapeutics by 8.1% during the fourth quarter. GW&K Investment Management LLC now owns 297,349 shares of the biopharmaceutical company’s stock worth $4,279,000 after purchasing an additional 22,289 shares during the last quarter. Mutual of America Capital Management LLC boosted its holdings in shares of Amicus Therapeutics by 165.3% during the fourth quarter. Mutual of America Capital Management LLC now owns 207,960 shares of the biopharmaceutical company’s stock worth $2,993,000 after purchasing an additional 129,560 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in shares of Amicus Therapeutics by 6.1% during the fourth quarter. Victory Capital Management Inc. now owns 2,644,924 shares of the biopharmaceutical company’s stock worth $38,061,000 after purchasing an additional 151,755 shares during the last quarter.

NASDAQ FOLD traded down $0.53 during mid-day trading on Wednesday, hitting $16.21. The stock had a trading volume of 1,260,149 shares, compared to its average volume of 2,970,288. Amicus Therapeutics has a 52-week low of $7.46 and a 52-week high of $17.40. The company has a market capitalization of $3.16 billion, a P/E ratio of -5.55 and a beta of 1.48. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.21 and a quick ratio of 4.15.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.